- Home
- PRPO vs APVO Comparison
PRPO vs APVO Comparison
Compare PRPO & APVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRPO
- APVO
- Stock Information
- Founded
- PRPO N/A
- APVO 2016
- Country
- PRPO United States
- APVO United States
- Employees
- PRPO N/A
- APVO N/A
- Industry
- PRPO Biotechnology: Laboratory Analytical Instruments
- APVO Biotechnology: Pharmaceutical Preparations
- Sector
- PRPO Industrials
- APVO Health Care
- Exchange
- PRPO Nasdaq
- APVO Nasdaq
- Market Cap
- PRPO 22.0M
- APVO 4.9M
- IPO Year
- PRPO N/A
- APVO N/A
- Fundamental
- Price
- PRPO $17.55
- APVO $1.41
- Analyst Decision
- PRPO
- APVO Strong Buy
- Analyst Count
- PRPO 0
- APVO 1
- Target Price
- PRPO N/A
- APVO $5,920.00
- AVG Volume (30 Days)
- PRPO 16.8K
- APVO 6.1M
- Earning Date
- PRPO 11-05-2025
- APVO 11-06-2025
- Dividend Yield
- PRPO N/A
- APVO N/A
- EPS Growth
- PRPO N/A
- APVO N/A
- EPS
- PRPO N/A
- APVO N/A
- Revenue
- PRPO $21,242,000.00
- APVO N/A
- Revenue This Year
- PRPO N/A
- APVO N/A
- Revenue Next Year
- PRPO N/A
- APVO N/A
- P/E Ratio
- PRPO N/A
- APVO N/A
- Revenue Growth
- PRPO 27.05
- APVO N/A
- 52 Week Low
- PRPO $3.90
- APVO $1.32
- 52 Week High
- PRPO $22.38
- APVO $381.10
- Technical
- Relative Strength Index (RSI)
- PRPO 53.87
- APVO 27.81
- Support Level
- PRPO $19.40
- APVO $1.40
- Resistance Level
- PRPO $22.38
- APVO $2.71
- Average True Range (ATR)
- PRPO 1.39
- APVO 0.21
- MACD
- PRPO -0.01
- APVO 0.03
- Stochastic Oscillator
- PRPO 40.33
- APVO 6.47
About PRPO Precipio Inc.
Precipio Inc is a healthcare solutions company focused on cancer diagnostics. It focuses on addressing the problem of cancer misdiagnoses by developing solutions to mitigate the root causes of this problem in the form of diagnostic products, reagents, and services. The company operates Clinical Laboratory Improvement Amendments laboratories in both the New Haven, Connecticut and Omaha, Nebraska locations providing essential blood cancer diagnostics to office-based oncologists in many states nationwide. It provides new technologies to the oncology diagnostic laboratory market in the form of HemeScreen and IV-Cell product offerings. The company generates the majority of its revenue from third-party payers.
About APVO Aptevo Therapeutics Inc.
Aptevo Therapeutics Inc is a clinical-stage research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidates are; ALG.APV-527, which targets co-stimulatory receptors and tumor antigens, and CD3xCD123, which is being developed as a potential treatment of frontline acute myelogenous leukemia. The company's preclinical candidates, APVO711, APVO0442, and APVO603, are being developed using the ADAPTIR modular protein technology platform. The company's versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.